ORIGINAL_ARTICLE
Predictive factors of short-term survival from acute myocardial infarction in early and late patients in Isfahan and Najafabad, Iran
BACKGROUND: Cardiovascular disease (CVD) is the primary cause of mortality in the world and Iran. The aim of this study was to determine the prognostic factors of short-term survival from acute myocardial infarction (AMI) in early and late patients in the Najafabad and Isfahan County, Iran. METHODS: This hospital-based cohort study was conducted using the hospital registry of 1999-2009 in Iran. All patients (n = 14426) with an AMI referred to hospitals of Isfahan and Najafabad were investigated. To determine prognostic factors of short-term (28-days) survival in early and late patients, unadjusted and adjusted hazard ratio (HR) was calculated using univariate and multivariate Cox regression. RESULTS: The short-term (28-day) survival rate of early and late patients was 96.6 and 89.4% (P < 0.001), respectively. In 80.0% of early and 79.3% of late patients, mortality occurred during the first 7 days of disease occurrence. HR of death was higher in women in the two groups; it was 1.97 in early patients was [confidence interval (CI) 95%: 1.32-2.92] and 1.35 in late patients (CI 95%: 1.19-1.53) compared to men. HR of death had a rising trend with the increasing of age in the two groups. CONCLUSION: Short-term survival rate was higher in early patients than in late patients. In addition, case fatality rate (CFR) of AMI in women was higher than in men. In both groups, sex, age, an atomic location of myocardial infarction based on the International Classification of Disease, Revision 10 (ICD10), cardiac enzymes, and clinical symptoms were significant predictors of survival in early and late patients following AMI.
https://arya.mui.ac.ir/article_10518_9a0e82d34e8dd41c0c7d7642555940cd.pdf
2016-03-03
59
67
Myocardial Infarction
Survival Rate
Early
Late
Regression Analysis
Iran
Mohammad
Abdolazimi
mohammad.abdolazimi@yahoo.com
1
Resident, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Alireza
Khosravi
a_mohamadii@yahoo.com
2
Associate Professor, Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Masoumeh
Sadeghi
3
Associate Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Abdollah
Mohammadian-Hafshejani
4
Social Determinants in Health Promotion Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran AND PhD Candidate, Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Nizal
Sarrafzadegan
5
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Hamid
Salehiniya
6
Zabol University of Medical Sciences, Zabol AND Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran
AUTHOR
Jafar
Golshahi
golshahi@med.mui.ac.ir
7
Associate Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
ORIGINAL_ARTICLE
Association of I405V polymorphism of colesteryl ester transfer protein gene with coronary artery disease in men with type 2 diabetes
BACKGROUND: Colesteryl ester transfer protein (CETP) plays a key role in the metabolism of lipoproteins; therefore, polymorphisms of its gene can affect susceptibility to coronary artery disease (CAD) in diabetes mellitus. The aim of the present study was to investigate association between I405V polymorphism of CETP gene and risk of CAD in patients with type 2 diabetes mellitus. METHODS: The current case-control study was conducted on 143 patients with type 2 diabetes and angiographically diagnosed CAD and 150 patients with type 2 diabetes and without CAD. Genotyping was performed through polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The presence of CAD was defined as higher than 50% reduction in coronary artery diameter. RESULTS: The genotype frequencies of I405V polymorphism were II (27.3% vs. 23.2%), IV (61.5% vs. 67.5%), and VV (11.2% vs. 9.3%) in diabetic with CAD compared to diabetic without CAD (χ2 = 1.164) (P = 0.55). The I and V alleles were found at frequencies of 63.6% and 61.6% in the diabetic with CAD group and 36.4% and 38.4% in the diabetic without CAD group (χ2 = 0.263) (P = 0.60). No significant difference was observed between two groups in terms of genotype and allele frequency. Moreover, no significant association was observed between II, IV, and VV genotypes and lipid profiles in both groups. However, a significant difference was observed between genotype distributions of I405V polymorphism in men according to the severity of CAD. CONCLUSION: It is speculated that I405V polymorphism may be associated with the severity of coronary artery stenosis only in men with type 2 diabetes mellitus.
https://arya.mui.ac.ir/article_10519_62347e998c059bb2947862456238e602.pdf
2016-03-03
68
75
Cholesterol Ester Transfer Protein
Polymorphism
Type 2 Diabetes Mellitus
Coronary Artery Disease
Fatameh
Karimpour
karimpour@yahoo.com
1
Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Ghorban
Mohammadzadeh
mohammadzadeh@ajums.ac.ir
2
Associate Professor, Hyperlipidemia Research Center AND Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
LEAD_AUTHOR
Alireza
Kheirollah
khaeirollah@yahoo.com
3
Assistant Professor, Cellular and Molecular Research Center AND Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Mohammad Ali
Ghaffari
ghaffarim@yahoo.com
4
Professor, Cellular and Molecular Research Center AND Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Azadeh
Saki
saki@yahoo.com
5
Assistant Professor, Department of Biostatistics and Epidemiology, School of Public Health, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
ORIGINAL_ARTICLE
Translation and validation of the Persian version of the treatment adherence questionnaire for patients with hypertension
BACKGROUND: Hypertension is a global public health crisis. Poorly controlled high blood pressure is one of the major factors contributed to this crisis. As lack of treatment adherence is often considered the main reason for this failure, the Treatment Adherence Questionnaire for Patient with Hypertension (TAQPH) was developed. Since this questionnaire should be reliable and strongly valid to be used in clinics and research, this study was performed to test the reliability and validity of the TAQPH. METHODS: A cross-sectional study was conducted to validate the Persian version of TAQPH after using a modified forward/backward translation procedure. A total of 330 hypertensive patients were participated in this study. Construct and criterion validity, Cronbach¢s alpha, and test-retest reliability were used to validate the Persian scale. RESULTS: Data analysis showed that the scale had excellent stability (intraclass correlation = 0.95) and good acceptability of internal consistency (α = 0.80). The exploratory factor analysis (EFA) was meaningful but was not confirmed with confirmatory factor analysis (CFA). The scale score was correlated with Morisky Medication Adherence Scale (MMAS) score (Ρ = 0.27). CONCLUSION: In total, most of the psychometric properties of the 25-item P-TAQHP achieved the standard level and were sufficient to recommend for general use.
https://arya.mui.ac.ir/article_10520_cfc9e3f5b55778e41b28a56b677c0131.pdf
2016-03-01
76
86
Hypertension
Treatment Adherence
Validation
Questionnaires
Mahlagha
Dehghan
m_dehghan86@yahoo.com
1
Assistant Professor, Department of Medical Surgical Nursing, School of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran
LEAD_AUTHOR
Nahid
Dehghan-Nayeri
nahid.nayeri@gmail.com
2
Professor, Nursing and Midwifery Care Research Center, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Sedigheh
Iranmanesh
s_iranmanesh@kmu.ac.ir
3
Assistant Professor, Department of Medical Surgical Nursing, School of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran
AUTHOR
ORIGINAL_ARTICLE
Biochemical effects of oleuropein in gentamicin-induced nephrotoxicity in rats
BACKGROUND: Oleuropein is a natural antioxidant and scavenging free radicals. In the present study, we examined effect of oleuropein on the paraoxonase 1 (PON1) activity, lipid peroxidation, lipid profile, atherogenic indexes, and relationship of PON1 activity by high-density lipoprotein-cholesterol (HDL-C) and atherogenic indices in gentamicin (GM)-induced nephrotoxicity in rats. METHODS: This is a lab trial study in Khorramabad, Lorestan province of Iran (2013). 30 Sprague-Dawley rats were divided into three groups to receive saline; GM, 100 mg/kg/day; and GM plus oleuropein by 15 mg/kg intraperitoneal daily, respectively. After 12 days, animals were anesthetized, blood samples were also collected before killing to measure the levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), and very LDL (VLDL), HDL-C, atherogenic index, lipid peroxidation, and the activities of PON1 of all groups were analyzed. Data were analyzed, and P < 0.050 was considered significant. RESULTS: Oleuropein significantly decreased lipid peroxidation, TG, TC, LDL, VLDL, atherogenic index, atherogenic coefficient (AC), and cardiac risk ratio (CRR). HDL-C level was significantly increased when treated with oleuropein. The activity of PON1 in treated animals was (62.64 ± 8.68) that it was significantly higher than untreated animals (47.06 ± 4.10) (P = 0.047). The activity of PON1 in the untreated nephrotoxic rats was significantly lower than that of control animals (77.84 ± 9.43) (P = 0.030). Furthermore, the activity of PON1 correlated positively with HDL-C and negatively with AC, CRR 1, and CRR 2 in the treated group with oleuropein. CONCLUSION: This study showed that oleuropein improves PON1 activity, lipid profile, and atherogenic index and can probably decrease the risk of cardiovascular death in nephrotoxic patients.
https://arya.mui.ac.ir/article_10521_dc71a01271b09085c33061d61b7b8795.pdf
2016-03-03
87
93
Gentamicin
Paraoxonase 1
Lipid Peroxidation
Nephrotoxicity
Lipid, Rat
Atherogenic Index
Oleuropein
Hassan
Ahmadvand
hassan_a46@yahoo.com
1
Razi Herbal Medicine Research Center AND Department of Biochemistry, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
AUTHOR
Shahrokh
Bagheri
sbg1660@yahoo.com
2
Department of Biochemistry, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
LEAD_AUTHOR
Ahmad
Tamjidi-Poor
3
Razi Herbal Medicine Research Center, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
AUTHOR
Mostafa
Cheraghi
4
Department of Cardiology, School of Medicine, Lorestan University of Medical, Sciences, Khorramabad, Iran
AUTHOR
Mozhgan
Azadpour
5
Razi Herbal Researches Center, Lorestan University of Medical Sciences, Khorramabad, Iran
AUTHOR
Behrouz
Ezatpour
6
Razi Herbal Medicine Research Center, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
AUTHOR
Sanaz
Moghadam
7
Razi Herbal Medicine Research Center, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
AUTHOR
Gholamreza
Shahsavari
8
Department of Biochemistry, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
AUTHOR
Masumeh
Jalalvand
9
Department of Immunology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
AUTHOR
ORIGINAL_ARTICLE
Policy makers’ viewpoints on implementation of the World Health Organization Framework Convention on Tobacco Control in Iran: A qualitative investigation of program facilitators
Background: The epidemic of smoking is a great concern of health systems. Moreover, the number of smokers is increasing worldwide and this has led to an escalating trend of morbidity, mortality, and burden of smoking-related diseases. Therefore, monitoring the implementation of tobacco control laws in different countries is of extreme importance. This study aimed to describe policy makers’ experiences and perceptions of the facilitating factors of the implementation of the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) in Iran. Methods: This was a qualitative research in which data were collected through individual interviews. The participants included policy makers who were members of the national assembly for tobacco control. In this study, 13 unstructured interviews of about 45 to 60 minutes duration were conducted in an extrapolative manner. The qualitative content analysis method was applied until extrapolation of basic themes was complete. Results: As a result of the analysis, the themes of performance through training, through research, through intersectoral collaboration, and through setting priorities emerged. The emerged themes connote some critical points that have key roles in promoting the effective implementation of the WHO FCTC. Furthermore, the main role of the health sector becomes predominant. Conclusion: The study findings suggested the managed and coordinated work as one of the main facilitating factors of the implementation of the WHO FCTC at a national level.
https://arya.mui.ac.ir/article_10522_9607bc03591799843e482e14b0e640e7.pdf
2016-03-01
94
99
Tobacco
Policy Makers
Qualitative
WHO
FCTC
Iran
Nizal
Sarrafzadegan
nsarrafzadegan@gmail.com
1
Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Katayoun
Rabiei
ktrabiei@gmail.com
2
PhD Candidate, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Mousa
Alavi
mousa_alavi@yahoo.com
3
Assistant Professor, Nursing and Midwifery Care Research Center, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Roya
Kelishadi
roya.kelishadi@gmail.com
4
Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Leila
Manzouri
manzourileila@yahoo.com
5
Assistant Professor, Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
AUTHOR
Heidarali
Abedi
drhabedi@gmail.com
6
Professor, School of Nursing and Midwifery, Islamic Azad University, Khorasgan Branch (Isfahan), Isfahan, Iran
AUTHOR
Khadijeh
Fereydoun-Mohaseli
khfermo@yahoo.com
7
National Tobacco Control Secretariat, Ministry of Health, Tehran, Iran
AUTHOR
Hasan
Azaripour-Masooleh
hazaripour@yahoo.com
8
General Practitioner, Social Security Organization, Tehran, Iran
AUTHOR
Hamidreza
Roohafza
hroohafza@gmail.com
9
Assistant Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Gholamreza
Heidari
ghrheydari@nritld.ac.ir
10
Tobacco Prevention and Control Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
(1) Tobacco or health : a global status report. Geneva; World Health Organization; 1997; 1997.
1
(2) Edwards R, Thomson G, Wilson N, Waa A, Bullen C, O'Dea D, et al. After the smoke has cleared: evaluation of the impact of a new national smoke-free law in New Zealand. Tob Control 2008 Feb;17(1):e2.
2
(3) Farzadfar F, Danaei G, Namdaritabar H, Rajaratnam JK, Marcus JR, Khosravi A, et al. National and subnational mortality effects of metabolic risk factors and smoking in Iran: a comparative risk assessment. Popul Health Metr 2011;9(1):55.
3
(4) Kelishadi R, Ardalan G, Gheiratmand R, Majdzadeh R, Delavari A, Heshmat R, et al. Smoking behavior and its influencing factors in a national-representative sample of Iranian adolescents: CASPIAN study. Preventive medicine 2006;42(6):423-6.
4
(5) What is the cost of Iranian daily smoking? How many percent of girls smoke. Asae' Kabar news. 21 May 2013 [In Persian]. Available on: goo.gl/Y4IIli
5
(6) FIFTY-SIXTH WORLD HEALTH ASSEMBLY. WHO Framework Convention on Tobacco Control. Article 11:Packaging and labelling of tobacco products. 5-21-2003.
6
(7) World Health Organization. Framework Convention on Tobacco Control.Geneva, WHO, 2003 Available on: http://www.who.int/tobacco/framework/download/en/ (Accessed 17 December 2004).
7
(8) The Government of the Islamic Republic's accession to the World Health Organization Framework Convention on Tobacco Control. Available on: http://rc.majlis.ir/fa/law/show/97946
8
(9) Interactive Word-based WHO FCTC Reporting Instrument and Cover Note/Instructions. 2011.
9
(10) The International Tobacco Control Policy Evaluation Project Official Website. Available on: http://www.itcproject.org/
10
(11) Fong GT, Cummings KM, Borland R, Hastings G, Hyland A, Giovino GA, et al. The conceptual framework of the international tobacco control (ITC) policy evaluation project. Tobacco Control 2006;15(suppl 3):iii3-iii11.
11
(12) Erguder T, Çak r B, Aslan D, Warren C, Jones N, Asma S. Evaluation of the use of Global Youth Tobacco Survey (GYTS) data for developing evidence-based tobacco control policies in Turkey. BMC Public Health 2008;8(Suppl 1):S4.
12
(13) Sarrafzadegan N, Kelishadi R, Rabiei K, Abedi H, Fereydoun Mohaseli K, Azaripour Masooleh H, et al. A comprehensive model to evaluate implementation of the world health organization framework convention of tobacco control. Iranian Journal of Nursing and Midwifery Research 2012;17(3).
13
(14) Watson R. Nursing research: designs and methods. Elsevier Health Sciences; 2008.
14
(15) Joossens L. From public health to international law: possible protocols for inclusion in the Framework Convention on Tobacco Control. Bulletin of the World Health Organization 2000;78(7).
15
(16) Siahpush M, McNeill A, Borland R, Fong G. Socioeconomic variations in nicotine dependence, self-efficacy, and intention to quit across four countries: findings from the International Tobacco Control (ITC) Four Country Survey. Tobacco control 2006;15(suppl 3).
16
(17) Hafez N, Ling PM. How Philip Morris built Marlboro into a global brand for young adults: implications for international tobacco control. Tobacco control 2005;14(4).
17
(18) Thrasher JF, Chaloupka F, Hammond D, Fong G, Borland R, Hastings G, et al. [Evaluating tobacco control policy in Latin American countries during the era of the Framework Convention on Tobacco Control]. Salud publica de Mexico 2006;48 Suppl 1.
18
(19) Heath J, Andrews J. Using evidence-based educational strategies to increase knowledge and skills in tobacco cessation. Nursing research 2006;55(4 Suppl).
19
(20) Chaudhry K. Tobacco control in India. Fifty years of cancer control in India Agarwal SP, Rao YN, Gupta S, Editors Directorate General of Health Services, Govt of India, New Delhi, India 2002.
20
(21) McMurray A, Clendon J. Community Health & Wellness: Primary Health Care in Practice. Elsevier Australia; 2010.
21
(22) Sinha DN, Reddy KS, Rahman K, Warren CW, Jones NR, Asma S. Linking Global Youth Tobacco Survey (GYTS) data to the WHO framework convention on tobacco control: the case for India. Indian journal of public health 2006;50(2).
22
(23) Moher M, Hey K, Lancaster T. Workplace interventions for smoking cessation. Cochrane database of systematic reviews 2005;(2).
23
(24) Edwards R, Thomson G, Wilson N, Waa A, Bullen C, O'Dea D, et al. After the smoke has cleared: evaluation of the impact of a new national smoke-free law in New Zealand. Tobacco control 2008;17(1).
24
(25) Park K, Kim DS, Park DJ, Lee SK. Tobacco control in Korea. Medicine and law 2004;23(4).
25
ORIGINAL_ARTICLE
Saphenous vein graft aneurysm: A case report
BACKGROUND: Saphenous vein graft aneurysms (SVGAs) are rare seen issues after coronary artery bypass graft operation which may lead to major complications including compression of adjacent structure, myocardial ischemia, rupture, and even death. CASE REPORT: We report a patient with recurrent SVGA and its treatment by percutaneous intervention with a covered stent, the diagnostic and treatment procedure were based on contrast enhanced computed tomography and myocardial perfusion scintigraphy. DISCUSSION: Multimodality imaging is required to demonstrate the true size and complications of the SVGA, the relationship among the adjacent structure, and to assess ischemia and size of myocardial territory supplied by the aneurysmal graft to decide treatment strategy.
https://arya.mui.ac.ir/article_10515_c9ad4d159ab7db8ef41ad2c9e811bbc3.pdf
2016-03-03
100
103
Coronary Aneurysm
Saphenous Vein
Stents
Computed Tomography
Coronary Artery Bypass Grafting
Ahmet Seyfeddin
Gurbuz
ahmetseyfeddingurbuz@hotmail.com
1
General Practitioner, Kartal Kosuyolu Heart Training and Research Hospital, Department of Cardiology, Istanbul, Turkey
LEAD_AUTHOR
Semi
Ozturk
semi_ozturk@yahoo.com
2
General Practitioner, Kartal Kosuyolu Heart Training and Research Hospital, Department of Cardiology, Istanbul, Turkey
AUTHOR
Emrah
Acar
dreacar44@gmail.com
3
General Practitioner, Kartal Kosuyolu Heart Training and Research Hospital, Department of Cardiology, Istanbul, Turkey
AUTHOR
Suleyman Cagan
Efe
scaganefe@gmail.com
4
General Practitioner, Kartal Kosuyolu Heart Training and Research Hospital, Department of Cardiology, Istanbul, Turkey
AUTHOR
Alev
Kilicgedik
akilicgedik@hotmail.com
5
General Practitioner, Kartal Kosuyolu Heart Training and Research Hospital, Department of Cardiology, Istanbul, Turkey
AUTHOR
Cevat
Kirma
ckirma@hotmail.com
6
Assistant Professor, Kartal Kosuyolu Heart Training and Research Hospital, Department of Cardiology, Istanbul, Turkey
AUTHOR
Ramirez FD, Hibbert B, Simard T, Pourdjabbar A, Wilson KR, Hibbert R, et al. Natural history and management of aortocoronary saphenous vein graft aneurysms: a systematic review of published cases. Circulation. 2012 Oct 30;126(18):2248-56
1
Douglas BP, Bulkley BH, Hutchins GM. Infected saphenous vein coronary artery bypass graft with mycotic aneurysm: fatal dehiscence of the proximal anastomosis. Chest. 1979;75:76 –77.
2
Ennis BM, Zientek DM, Ruggie NT, Billhardt RA, Klein LW. Characterization of a saphenous vein graft aneurysm by intravascular ultrasound and computerized three-dimensional reconstruction. Cathet Cardiovasc Diag. 1993;28:328 –331.
3
Kallis P, Keogh BE, Davies MJ. Pseudoaneurysm of aortocoronary vein graft secondary to late venous rupture: case report and literature review. Br Heart J. 1993;70:189 –192.
4
Werthman PE, Sutter FP, Flicker S, Goldman SM. Spontaneous late rupture of an aortocoronary saphenous vein graft. Ann Thorac Surg. 1991;51:664–666.
5
De Haan HPJ, Huysmans HA, Weeda HWH. Anastomotic pseudoaneurysm afteraorto-coronary bypass grafting. ThoracCardiovasc Surg. 1985;33:55–56.
6
Benchimol A, Harris CL, Desser KB, Fleming H. Aneurysms of an aorto coronary artery saphenous vein bypass graft: a case report. Vasc Surg. 1975;9:261–264.
7
Spraycar M. ed. .Stedman's Medical Dictionary. 26th ed. Baltimore: Williams & Wilkins, 1995: 1450
8
Bhindi R, Newton J, Westaby S, Wilson N, Ormerod OJ, Uberoi R. Stent-graft repair of coronary vein graft aneurysm. J Vasc Interv Radiol 2009;20(5):649–51.
9
Rahim SA, Pitta SR, Rihal CS. Saphenous vein graft aneurysm. J Am CollCardiol 2009;53(May (20)):1918.
10
Kapadia S. Stent-assisted detachable coil embolization of aneurysms in the coronary circulation. Catheter CardiovascInterv 2006;68(September (3)):409 15.
11
Mylonas I, Sakata Y, Salinger MH, Feldman T. Successful closure of a giant true saphenous vein graft aneurysm using the Amplatzer vascular plug. Catheter CardiovascInterv 2006;67(4):611–6.
12
Sonnenberg B, Rutledge J, Welsh RC. Occlusion of a large expanding saphenous vein bypass graft aneurysm with percutaneously injected ethylene–vinyl alcohol copolymer. JACC CardiovascInterv 2010;3(October (10)): 1089–90
13
Natural History and Management of Aortocoronary Saphenous Vein Graft Aneurysms. A Systematic Review of Published Cases.Circulation. 2012; 126: 2248-2256
14
ORIGINAL_ARTICLE
The vasorelaxant effect of simvastatin in isolated aorta from diabetic rats
BACKGROUND: The increasing incidence of diabetes mellitus (DM) is of great clinical significance. In this study, we aimed to investigate whether exposure of endothelium-intact aortic rings to simvastatin could have a vasorelaxant effect in diabetic rats. METHODS: For induction of diabetes, streptozotocin (STZ) (60 mg/kg, i.p., single dose) was used. After 1 month, the cumulative reaction of isolated endothelium-intact aortic rings was determined to KCl and phenylephrine (PE) in the absence and presence of nitric oxide (NO) synthase inhibitor, i.e., nitro-L-arginine-methyl ester (L-NAME), and prostaglandin synthesis inhibitor, i.e., indomethacin. Meanwhile, the role of extracellular calcium was assessed in this respect. RESULTS: At the end of the study, the addition of simvastatin (at a concentration ≥ 10−5 M) caused a significant concentration-dependent relaxation response of PE-precontracted aortic rings for both control and diabetic groups (at a significant difference of P < 0.050), and this difference did not exist for KCl-precontracted aortic rings. Furthermore, both L-NAME (100 µM) and indomethacin (10 µM) significantly diminished the vasorelaxant response following simvastatin addition. Meanwhile, there was no statistically significant difference between control and diabetic groups in the absence of extracellular calcium. CONCLUSION: The results of this study suggest that simvastatin is able to relax PE-precontracted aortic rings isolated from STZ-diabetic rats via modulation of NO- and prostaglandin-dependent signaling and its effect is not via modulation of calcium mobilization from intracellular stores.
https://arya.mui.ac.ir/article_10516_d6ab33b40999fdec70b90fe15f0b7f0d.pdf
2016-04-10
104
108
Simvastatin
Aorta
Diabetes Mellitus
Farshad
Roghani-Dehkordi
frdehkordi@gmail.com
1
Associate Professor, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Mehrdad
Roghani
2
Professor, Neurophysiology Research Center, Shahed University, Tehran, Iran
AUTHOR
ORIGINAL_ARTICLE
One year follow up effect of renal sympathetic denervation in patients with resistant hypertension
BACKGROUND: Resistant hypertension is a common clinical problem of blood pressure that is not controlled despite the simultaneous application of multiple antihypertensive agents. Ablation of renal afferent nerves has been applied and proved to decrease hypertension and injuries produced by severe sympathetic hyperactivity. The main objective of this study was to investigate the long-term effect of renal artery sympathetic ablation and its complications in patients with treatment-resistant hypertension. METHODS: In this prospective study which done between March 2012 and November 2013, 30 patients with resistant arterial hypertension despite treatment with ≥3 antihypertensive drugs-were randomly enrolled in this self-control clinical study in Isfahan, Iran. The patients were treated with the renal denervation procedure; the femoral artery was accessed with the standard endovascular technique and the Symplicity catheter was advanced into the renal artery and connected to a radiofrequency generator. Before and 12 months after renal denervation procedure waist, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), metabolic syndrome, fasting blood sugar (FBS), high-density lipoprotein (HDL), and triglyceride were measured in all patients. RESULTS: Both mean SBP and DBP were significantly decreased, 12 months after renal denervation (P < 0.001). The frequency of metabolic syndrome was not significantly different after renal denervation in compare to baseline (P = 0.174). Furthermore, a significant decreased in FBS and triglyceride was observed in compare to baseline (P = 0.001). CONCLUSION: This study highlighted the role of renal sympathetic denervation as a modern and secure catheter-based method for sustained reduction hypertension in treatment-resistant cases.
https://arya.mui.ac.ir/article_10517_7c2c2dc5d686fb9e903dd2252c56b4b5.pdf
2016-03-01
109
113
Hypertension Resistant
Renal Sympathetic Denervation
Renal Artery Ablation
Angiography
Renal Sympathectomy
Masoud
Pourmoghaddas
m_pourmoghadas@med.mui.ac.ir
1
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Alireza
Khosravi
akbari.epi@gmail.com
2
Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Mohammadreza
Akhbari
mr_akhbari55@yahoo.com
3
Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Mojtaba
Akbari
m_akbari@med.mui.ac.ir
4
PhD Student, Department of Epidemiology, School of Health and Nutrition, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Mohamadreza
Pourbehi
5
Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Fereshteh
Ziaei
6
Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Leila
Salehizade
7
Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Nahid
Sistan
8
Nurse, Chamran Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Masoumeh
Esmaeili
9
Nurse, Chamran Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Peyman
Bidram
10
Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
ORIGINAL_ARTICLE
Journal Index
Click to download the index of this issue.
https://arya.mui.ac.ir/article_10514_b5b8d0bf9275bd548f74f2caebea92bd.pdf
2016-03-01
Index
Journal
arya@crc.mui.ac.ir
1
LEAD_AUTHOR